The expansion of Vγ9Vδ2 (Vδ2) T cells from a large cohort of peripheral blood mononuclear cell (PBMC) donors for the development of γδ T cell-based cancer therapies revealed notable differences in CD16 expression (Fig. 1a–d; Supplementary Fig. 1a, b). Here, FCGR3A is linked to cancer.